Patents by Inventor Joerg Rosenberg

Joerg Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210353555
    Abstract: The present invention relates to nanoparticles based on optionally alkoxylated poly(alkyl cyanoacrylates) having a defined molecular mass and dispersity, a method for preparing such nanoparticles, compositions comprising such nanoparticles and medical uses thereof. The invention further relates to the use of optionally alkoxylated poly(alkyl cyanoacrylates) having a defined molecular mass and dispersity for preparing nanoparticles as well as to a method for preparing such polymers.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 18, 2021
    Inventors: Anamarija CURIC, Benjamin-Luca KELLER, Thomas MÜLLER, Jörg ROSENBERG
  • Patent number: 10653625
    Abstract: A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 19, 2020
    Assignee: Abbvie Deutschland GmbH & Co. KG
    Inventors: Jörg Rosenberg, Markus Mägerlein, Bernd Liepold, Jörg Breitenbach
  • Publication number: 20180325833
    Abstract: The present invention relates to nanoparticles based on optionally alkoxylated poly(alkyl cyanoacrylates) having a defined molecular mass and dispersity, a method for preparing such nanoparticles, compositions comprising such nanoparticles and medical uses thereof. The invention further relates to the use of optionally alkoxylated poly(alkyl cyanoacrylates) having a defined molecular mass and dispersity for preparing nanoparticles as well as to a method for preparing such polymers.
    Type: Application
    Filed: October 27, 2016
    Publication date: November 15, 2018
    Inventors: Anamarija CURIC, Benjamin-Luca KELLER, Thomas MÜLLER, Jörg ROSENBERG
  • Publication number: 20180185287
    Abstract: A solid dosage form having a matrix with at least one active compound dispersed homogeneously in the matrix, which is obtainable by melting a powder mixture, wherein the powder mixture comprises at least one thermoplastic binder and a combination of highly disperse silica and at least one inorganic pigment, is described. The co-use of the highly disperse silica and the inorganic pigments leads to better flow properties of the powder mixture, has the effect of a faster release of the active compound from the dosage forms obtained, and imparts a visually pleasing appearance to the dosage forms. A process for the preparation of the dosage form is also described.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 5, 2018
    Inventors: Katja Fastnacht, Matthias Degenhardt, Gunther Berndl, Jörg Rosenberg, Jörg Breitenbach
  • Patent number: 9616130
    Abstract: Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono-and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: April 11, 2017
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Publication number: 20170014348
    Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventors: Joerg Breitenbach, Salih Durak, Sandeep Dutta, Thomas Y. Kessler, Wei Liu, Friedrich W. Richter, Joerg Rosenberg, Gerd Woehrle
  • Patent number: 9414992
    Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element (14) which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: August 16, 2016
    Assignee: Abbvie Deutschland GmbH & CO KG
    Inventors: Thomas Kessler, Jörg Breitenbach, Christoph Schmidt, Matthias Degenhardt, Jörg Rosenberg, Harald Krull, Gunther Berndl
  • Patent number: 9205027
    Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (A), (ii) at least one mixing section (B), and (iii) a discharging section (E), wherein the processing element(s) defining the mixing section (B) comprise(s) a mixing element (11, 12, 13) that is derived from a screw type element (FIG. 2).
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: December 8, 2015
    Assignee: Abbvie Deutschland GmbH & CO KG
    Inventors: Thomas Kessler, Jörg Breitenbach, Christoph Schmidt, Matthias Degenhardt, Jörg Rosenberg, Harald Krull
  • Publication number: 20150314000
    Abstract: Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.
    Type: Application
    Filed: July 14, 2015
    Publication date: November 5, 2015
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Patent number: 9078921
    Abstract: A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: July 14, 2015
    Assignee: Abbvie Deutschland GmbH & Co KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Patent number: 9028876
    Abstract: Rate-controlled particles, comprising compounds of the formula as a solid dispersion.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: May 12, 2015
    Assignee: Janssen R&D Ireland
    Inventors: Thomas Hantke, Bettina Rehbock, Jörg Rosenberg, Jörg Breitenbach
  • Publication number: 20140187561
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 3, 2014
    Inventors: Russell Drew Cink, Joseph B. Paterson, Jr., Yi Gao, Geoff G.Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Publication number: 20140179721
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 5° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
  • Publication number: 20140135388
    Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 15, 2014
    Inventors: Gunther BERNDL, Joerg BREITENBACH, Robert HEGER, Joerg ROSENBERG, Michael STADLER, Peter WILKE
  • Publication number: 20140094479
    Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (A), (ii) at least one mixing section (B), and (iii) a discharging section (E), wherein the processing element(s) defining the mixing section (B) comprise(s) a mixing element (11, 12, 13) that is derived from a screw type element (FIG. 2).
    Type: Application
    Filed: December 2, 2013
    Publication date: April 3, 2014
    Applicant: AbbVie Deutschland GmbH & Co. KG
    Inventors: Thomas Kessler, Jörg Breitenbach, Christoph Schmidt, Matthias Degenhardt, Jörg Rosenberg, Harald Krull
  • Publication number: 20140087060
    Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element (14) which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.
    Type: Application
    Filed: December 2, 2013
    Publication date: March 27, 2014
    Applicant: AbbVie Deutschland GmbH & Co. KG
    Inventors: Thomas Kessler, Jörg Breitenbach, Christoph Schmidt, Matthias Degenhardt, Jörg Rosenberg, Harald Krull, Gunther Berndl
  • Patent number: 8673344
    Abstract: The present invention relates to a solid dosage form with at least one film, which contains an active substance at least in sections, and the concentration of the active substance in the film or in the films has a gradient in a direction normal to the thickness of film. The invention further relates to a method of producing a solid dosage form, in which at least one film is produced, containing an active substance at least in sections, with the concentration of the active substance having a gradient in the longitudinal direction of the film.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: March 18, 2014
    Assignee: Abbvie Deutschland GmbH & Co. KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Peter Heilmann, Helmuth Steininger
  • Patent number: 8470347
    Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: June 25, 2013
    Assignee: AbbVie Deutschland GmbH and Co KG
    Inventors: Gunther Berndl, Jörg Breitenbach, Robert Heger, Michael Stadler, Peter Wilke, Jörg Rosenberg
  • Patent number: 8399015
    Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: March 19, 2013
    Assignee: AbbVie Inc.
    Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
  • Patent number: 8377952
    Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: February 19, 2013
    Assignee: Abbott Laboratories
    Inventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh